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medications, absolute CD4 count did not change (389 vs. 392The clinical characteristics and antiretroviral dosing patterns
cells/mL, P  0.11) during similar periods of follow-up. Noof HIV-infected patients receiving dialysis.
difference was seen between initial and current HIV RNABackground. Human immunodeficiency virus (HIV)-related
levels for either group. Among patients receiving antiretroviralrenal disease is the third leading cause of end-stage renal disease
medications, there were significant variations in dosing regi-(ESRD) among African Americans aged 24 to 60 years. This
mens. The greatest variation was seen in the prescribing pat-study describes the clinical characteristics and antiretroviral
terns of lamivudine with a 12-fold difference among patients.dosing patterns of HIV-infected patients receiving dialysis to
Conclusion. The projected growth of the HIV-infected ESRDdefine the clinical needs of this growing population.
population requires a better understanding of the clinical needsMethods. Demographic and clinical information was collected
of this population. The high prevalence of coinfection withon all HIV-infected patients incident to dialysis after January 1,
hepatitis C as well as the wide variations in dosing patterns for1998 until January 1, 2001 at five medical centers. The cohort
antiretroviral medications are areas that require further investi-was described overall and by subgroups based on hepatitis
gation to minimize morbidity and mortality among this group.status, CD4 lymphocyte count, and use of antiretroviral ther-
apy. Continuous and categoric variables were compared using
either the Wilcoxon rank sum or Student t test and Fisher’s
exact or chi-square tests, as appropriate. Human immunodeficiency virus (HIV)-related renalResults. A total of 89 patients were included, 55 of whom
diseases are the third leading cause of end-stage renalwere alive at the time of data collection. The mean age was
disease (ESRD) among African Americans aged 20 to 6444.6 years (range, 22.7 to 66.9 years), 74.2% were male, and
83.2% patients were African Americans. While only 45.9% of years old [1]. While antiretroviral medications have been
patients undergoing renal biopsy were diagnosed with HIV- effective in slowing the progression of HIV-associated
associated nephropathy (HIVAN), the majority of patients nephropathy (HIVAN) [2–7], it is projected that due towho had not undergone biopsy carried the clinical diagnosis
the increasing numbers of patients living with acquiredof HIVAN (69.8%, P  0.03). Of the cohort, 19.7% tested
immunodeficiency syndrome (AIDS), the number ofhepatitis B surface antigen positive, and 67.1% had reactive
antibody tests for hepatitis C. Patients with hepatitis C were HIV-infected patients reaching ESRD will increase ex-
more likely to have experienced intravenous drug use as a risk ponentially over the next decade (abstract; Schwartz EJ
behavior for HIV acquisition (OR 8.2; 95% CI 2.39, 27.9; P  et al, J Am Soc Nephrol 2000: 11:165a, 2000).0.001] and to be older (OR 1.1 per year of age; 95% CI 1.02,
Prior to the use of highly active antiretroviral therapy1.2; P  0.01). A total of 60.7% of patients were receiving
(HAART), HIV-infected ESRD patients had a highantiretroviral medication at last follow-up. Among patients
alive and receiving antiretroviral medications at the time of data mortality rate with mean survival times of 3.0 months
collection, absolute CD4 count rose (268 vs. 339 cells/mL, P [8], 4.47 months [9], and 11.0 [10] months. Among HIV-
0.03), while among patients alive, but not receiving antiretroviral infected ESRD patients, higher absolute CD4 lympho-
cyte counts have been associated with prolonged survival
[10, 11]. Subsequently, an observational cohort study hasKey words: HIV-1, ESRD, hemodialysis, hepatitis C, antiretroviral
medications. demonstrated a longer mean survival time among patients
treated with HAART as compared to one or two antiret-Received for publication September 19, 2002
roviral drugs (mean, 28 vs. 13 months) [12]. More recently,and in revised form December 19, 2002
Accepted for publication February 4, 2003 an analysis of USRDS data reveals an improved survival
for patients beginning dialysis during and since 1997 [13]. 2003 by the International Society of Nephrology
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While conclusions regarding the absolute efficacy of anti- Data analysis
retroviral medications on mortality from these studies are Demographic and clinical characteristics, including
limited by either small sample size [12] or lack of patient age at initiation of dialysis, gender, race, risk behaviors
level data on use of antiretroviral medications [13], these for HIV acquisition, duration of HIV infection prior to
data are compelling. They suggest a temporal relation- initiation of dialysis, and etiology of renal disease, were
ship between availability of protease inhibitors and im- described for patients overall and for patients alive at
provement in survival that may be similar to that seen the time of data collection (between April 2001 and July
among patients with normal kidney function [14, 15]. 2001).
Little information is available on dosing and variations in
The frequency with which patients underwent diag-efficacy of antiretroviral medications among HIV-infected
nostic renal biopsy prior to the institution of renal re-patients with ESRD [16–18]. Further, little is known about
placement therapy was calculated. The types and fre-the demographic and clinical characteristics of the popu-
quency of histologic lesions identified among patientslation of patients who are HIV-infected and currently
undergoing renal biopsy were compared to the presumedreceiving renal replacement therapy. Given the expected
etiology (herein termed clinical diagnosis) of renal dis-exponential increase in the number of HIV-infected pa-
ease among patients not undergoing renal biopsy.tients receiving renal replacement therapy, this study
Initial (at incidence to ESRD) and most current abso-was undertaken to describe the clinical characteristics
lute CD4 lymphocyte count and HIV RNA level wereand antiretroviral dosing patterns among HIV-infected
described for all patients and subsequently for patientspatients receiving hemodialysis to better understand the
alive at the time of data collection stratified on whetherclinical needs of this population.
or not patients were receiving antiretroviral therapy.
Due to the nonnormal distribution of HIV RNA levels,
METHODS comparison of these values were performed on log-trans-
Study subjects and data collection formed measurements. Information on antiretroviral medi-
This retrospective cohort study describes the epidemi- cation use and dose were described for all patients and
ology, clinical history, and clinical practice patterns of for patients alive at the time of data collection. The use
all HIV-infected patients with ESRD receiving renal re- of antiretroviral medication among patients with current
placement therapy (hemodialysis and peritoneal dialysis) CD4 lymphocyte counts 200, 201 to 500, and 500
at Duke University Medical Center, Metrohealth Medi- cells were compared. Among patients alive at the time of
cal Center, Mount Sinai Medical Center, Indiana Univer- data collection, most current absolute CD4 lymphocyte
sity Medical Center, and San Francisco General Hospi- count and HIV RNA level were compared for patients
tal. These sites are represented by members of the Renal receiving and not receiving antiretroviral medication.
Working Group of the AIDS Clinical Trials Group. The frequency of a positive hepatitis C antibody and
All patients with documented HIV infection who be- hepatitis B surface antigen were calculated among all
gan receiving renal replacement therapy (hemodialysis patients in whom these tests had been performed. Asso-
or peritoneal dialysis) regardless of the etiology of renal ciations between a positive hepatitis C antibody or hepa-
disease (e.g., HIVAN, other HIV-related renal disease, titis B surface antigen were tested using logistic regres-
diabetes mellitus, hypertension) between January 1,1998 sion. Clinical and demographic variables of interest were
and January 1, 2001 were included. This period of time initially tested in both univariate and multivariable mod-
was chosen to provide a sample representative of patients
els. The frequency of types of hemodialysis vascular ac-treated during the HAART era. Patients were identified
cess was described for all patients receiving hemodialysisfor study through both the nephrologist and infectious
at the time of data collection or at the time of their death.diseases physicians at each institution. Information on
Erythropoietin dose and hematocrit were described forpatient demographics, medical history, dialysis treatment
patients alive at the time of data collection.characteristics, and medication use and dosing (at the
Continuous and categoric variables between subgroupstime of the last clinical encounter immediately preceding
of interest were compared using either the Wilcoxondata collection) was abstracted from each patient’s clini-
rank sum or Student t test and Fisher’s exact or chi-cal chart and dialysis record. This study was approved
square tests, as appropriate. The paired t test was usedby the Institutional Review Board of each institution.
to compare those continuous variables measured repeat-Because of the study design and methods, the Institu-
edly within individual patients (such as HIV RNA leveltional Review Board at each institution waived the re-
and CD4 lymphocyte count). All P values reportedquirement for consent. Therefore, no patient was con-
are two-sided, and all confidence intervals reported aretacted. All information was abstracted directly from the
95% CIs. All analyses were performed using Stata (ver-medical record, and data was collected without ability
to subsequently link it back to the individual. sion 7.0, College Station, TX, USA).
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Table 2. Renal diagnosis among human immunodeficiency virusTable 1. Clinical and demographic information for human
immunodeficiency virus (HIV)-infected patients (HIV)-infected patients undergoing and not undergoing biopsy
NotAll HIV-infected patients
HIV-infected alive at the time of Undergoing undergoing
Etiology biopsy biopsyVariable patients data collection
Number 89 58 HIVAN 45.9% (17)a 69.8% (30)a
Membranoproliferative glomerulonephritis 10.8% (4) 4.7% (2)Age (at initiation of dialysis)
years 44.6 (9.1) 43.9 (9.6) Diabetes mellitus 5.4% (2) 14.0% (6)
Hypertension 5.4% (2) 4.7% (2)Race
African American 74 (83.2%) 53 (91.4%) Amyloid 5.4% (2) 2.3% (1)
Chronic focal glomerulonephritis 2.7% (1)Hispanic 14 (15.7%) 5 (8.6%)
Caucasian 1 (1.1%) 0 Focal segmental glomerulosclerosis 5.4% (2)
Membranous glomerulopathy 2.7% (1)Gender % male 74.2% 74.1%
Risk behavior for Nonspecific 2.7% (1)
No tissue obtained 8.1% (3)HIV-acquisition
Intravenous drug use 47 (52.8%) 33 (56.9%) Mesangial glomerulonephritis 5.4% (2)
Heroin abuse 2.3% (1)Sexual exposure 35 (39.3%) 21 (36.2%)
Other 5 (5.6%) 4 (6.9%) Nephrotoxic drugs 2.3% (1)
Total 37 43Unknown 11 (12.4%) 6 (10.3%)
Average length of time HIVAN is HIV-associated nephropathy
between first documented aP  0.03 (HIVAN vs. all others)
infection and start of renal
replacement therapy years 5.6 (4.4) 4.9 (4.3)
Average length of time
receiving dialysis years 1.9 (2.1) 2.2 (2.3)
Dialysis modality diagnosed within 8 months of dialysis initiation. Eighty-
Hemodialysis 84 (94.4%) 54 (93.1%) four patients received hemodialysis, and five patients re-Peritoneal dialysis 5 (5.6%) 4 (6.9%)
ceived peritoneal dialysis. Fifty-eight were alive at the timeHepatitis C antibodya
Positive 49 (67.1%) 31 (60.8%) of data collection and currently receiving dialysis while
Negative 24 (32.9%) 20 (39.2%) 31 were deceased.Hepatitis B surface antigena
Of 41.6% of patients who underwent renal biopsy priorPositive 13 (19.7%) 6 (16.7%)
Negative 53 (80.3%) 40 (83.3%) to the institution of renal replacement therapy, 45.9% had
Hematocrit 32.5 (6.2) 34.0 (6.0) biopsy-proved HIVAN. Of patients who did not undergoAlbumin g/dL 3.1 (0.8) 3.4 (0.6)
renal biopsy, a greater proportion (69.8%) had the “clini-Route of epoetin alpha
administration cal” diagnosis of HIVAN (P  0.03) (Table 2).
Intravenous 49 (73.1%) 36 (76.6%)
Of 73 patients in whom it was tested, 49 (67.1%) hadSubcutaneous 18 (26.9%) 11 (23.4%)
Dose of epoetin alpha a positive hepatitis C antibody. In multivariable analyses,
units/kg/week patients with hepatitis C antibody were more likely to
Intravenous 319.9 (221.4) 282.0 (213.7)
have intravenous drug use as a risk behavior for HIVSubcutaneous 207.8 (124.7) 191.3 (137.5)
Patients receiving acquisition (OR 8.2; 95% CI 2.39, 27.9; P  0.001) and
antiretroviral therapy 54 (60.7%) 41 (70.7%) to be older (OR 1.1 per year of age; 95% CI 1.02, 1.2;
a Among patients with available results P  0.01).
Among the 66 patients in whom hepatitis B surface
antigen results were available, 13 (19.7%) were coin-
fected with hepatitis B. Univariate and multivariableRESULTS
analyses revealed only absolute CD4 lymphocyte count
Clinical and demographic characteristics were significantly associated with the presence of a posi-
Eighty-nine patients were identified for inclusion (Ta- tive hepatitis B surface antigen (OR 0.84 per increase
ble 1). The average age at initiation of dialysis was 44.6 in 10 cells; 95% CI 0.75, 0.95; P  0.006). No other
years (9.1 years). The majority of patients were African variables had a significant association with the presence
Americans (83.2%) and male (74.2%). The risk behavior of chronic hepatitis B infection.
of HIV acquisition for the majority of patients was intra-
CD4 count, HIV RNA level, and dosing patterns forvenous drug use (52.8%) and sexual exposure (39.3%).
antiretroviral medicationsThe average length of time since first documented HIV
infection was 7.94 years (range, 0.4 to 18.4 years). The A total of 60.7% (54 of 89 patients) were receiving
average length of time between first documented HIV antiretroviral medications at the time of data collection
infection and start of renal replacement therapy was 5.6 or the time of last follow-up. Among patients whose
years (range, 4.5 to 15.2 years). Seven patients were most current CD4 lymphocyte count was 200, 67.7%
diagnosed with HIV infection following the start of renal (21 of 31 patients) were receiving antiretroviral medica-
tions. The proportion of patients receiving antiretroviralreplacement therapy with six of the seven patients being
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Table 3. CD4 lymphocyte counts and human immunodeficiency virus (HIV) RNA levels
Patients alive at the time of data collection
Parameter All patients Receiving AR Not receiving AR
Initial CD4 count cells/mL 222 (90, 384)a 240 (160, 384)b 368 (201, 521)c
Current CD4 count cells/mL 264 (109, 468) 283 (174, 400) 412 (244, 518)
Initial HIV RNA level copies/mL 10,242 (517, 65,740) 2600 (389, 34,000)d 11,714 (1282, 18,820)e
Current HIV RNA level copies/mL 3953 (50, 46,599) 400 (50, 9678) 13,648 (400, 56,729)
AR is antiretroviral status at time of data collection
a Median (25th and 75th percentiles)
b P  0.03 comparing initial CD4 count to current CD4 count among patients receiving antiretrovirals medications
c P  0.11 comparing initial CD4 count to current CD4 count among patients not receiving antiretrovirals medications
d P  0.02 comparing initial HIV RNA level to current HIV RNA level among patients receiving antiretrovirals medications
e P  0.11 comparing initial HIV RNA level to current HIV RNA level among patients not receiving antiretrovirals medications
medications was unchanged among patients with CD4 cess (47.5%, N  30) (Table 5). Twelve (40%) of the
lymphocyte counts of 200 to 500 and500 cells at 71.4% 30 patients using a tunneled catheter as vascular access
(15 of 21 patients) and 48.6% (18 of 37 patients), respec- had another access that was available but not in use due
tively (P 0.14). At the time of their last clinical encoun- to the need for access maturation or surgical revision
ter, patients alive at the time of data collection were (nine patients had a native fistula and three patients had
more likely to be receiving antiretroviral medications a synthetic graft).
than patients who were deceased (Table 1) (70.7 vs.
41.9%, P  0.009). Among patients alive at the time of
DISCUSSIONdata collection, use of antiretroviral medications was
This study describes the clinical and demographic char-associated with an increase in absolute CD4 lympho-
acteristics, the dosing regimens for antiretroviral medica-cyte count over the study period (268 vs. 339 cells/mL,
tions, and the frequency of renal biopsy of HIV-infectedP 0.03). Among patients alive but not receiving antiret-
patients receiving renal replacement therapy in five med-roviral medications absolute CD4 count did not change
ical centers. Further, it describes a significant proportion(389 vs. 392 cells/mL, P  0.11) (Table 3). The period
of HIV-infected dialysis patients who are coinfected withof time between first and current CD4 count measure-
both HIV-1 and hepatitis C.ments were similar for groups receiving and not receiving
While slightly less than one half of patients who under-antiretroviral medications (2.3 vs. 2.3 years, P  0.93).
went renal biopsy prior to the institution of dialysis hadAmong patients alive and receiving antiretroviral medi-
the histologic diagnosis of HIVAN, a significantly greatercations at the time of data collection, HIV RNA level
proportion of patients who did not undergo renal biopsyfell (36,088 vs. 13,182 copies/mL, P 0.02), while among
were stated in the medical record to have HIVAN aspatients alive but not receiving antiretroviral medications
the “clinical” diagnosis. Given that noninvasive tests areHIV RNA level did not change (Table 3) (P  0.11).
unable to distinguish between HIVAN and other lesionsAmong patients receiving antiretroviral medications,
[19], this disparity suggests an overestimation of the fre-there were significant variations in dosing regimens of
quency of HIVAN and an underestimation of other renalindividual medications. Among patients receiving nucleo-
lesions that the HIV-infected patient may experience.side reverse transcriptase inhibitors, the greatest varia-
While biases may be introduced in the selection of pa-tion in regimen existed in the dosing of lamivudine and
tients to undergo renal biopsy, the proportion of patientszidovudine. Lamivudine was prescribed to 36 patients with
with HIVAN among the subgroup patients biopsied ina 12-fold range in dosage from 25 mg/day to 300 mg/day
this study is similar to the previously described propor-(Table 4 and Fig. 1A). Zidovudine was prescribed to 11
tions among patients receiving clinical care [19, 20] andpatients with a 14-fold range in dosage from 100 mg
patients undergoing autopsy [21]. While a number of thesethree times a week to 300 mg twice a day (Table 4 and
histologic lesions may be treated empirically, among cer-Fig. 1B). Variations in dosing regimen were similarly
tain patients, disease-specific therapy may aid in slowingseen among nonnucleoside reverse transcriptase inhibi-
the progression of their renal disease. More aggressivetors and protease inhibitors.
diagnostic testing may be warranted.
Hemodialysis modality and access While this study is limited in its ability to assess the
efficacy of antiretroviral agents on immune reconstitu-Five patients were undergoing peritoneal dialysis while
tion among dialysis patients, it suggests that absolutethe vast majority of patients (84 of 89) were undergoing
CD4 counts may be improved among dialysis patientshemodialysis. Among patients undergoing hemodialysis,
a tunneled catheter was the most frequent vascular ac- receiving these agents as compared with those who do
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Table 4. Dosing range for antiretroviral medications prescribed within patient cohort
Number of
patients
in whom
prescribed Minimum dose Maximum dose
Nucleoside reverse transcriptase inhibitors
Abacavir 3 300 mg/day 300 mg twice a day
Combivira 8 1 capsule/day 1 capsule three times a day
Didanosine 7 100 mg/day 200 mg twice a day
Lamivudine 36 25 mg/day 300 mg/day
Stavudine 33 10 mg/day 40 mg/day
Zidovudine 11 100 mg each Monday, Wednesday, and Friday 300 mg twice a day
Nonnucleoside reverse transcriptase inhibitors
Efavirenz 13 200 mg/day 600 mg/day
Nevirapine 11 200 mg/day 400 mg/day
Protease inhibitors
Indinavir 6 800 mg twice a day 800 mg three times a day
Nelfinavir 21 250 mg twice a day 1250 mg twice a day
Ritonavir 5 100 mg twice a day 500 mg twice a day
Saquinavir 2 400 mg twice a day 1200 mg three times a day
a Combination drug. Each capsule contains 150 mg lamivudine and 300 mg zidovudine.
Table 5. Frequency of dialysis access type in use at the time among
patients receiving hemodialysis
Frequency
Access (number)
Tunneled catheter with no other access available 28.5% (18)
Tunneled catheter with other access available but
not in use 19.0% (12)a
Native arteriovenous fistula 33.3% (21)
Synthetic arteriovenous graft 19.0% (12)
a Nine patients had a native arteriovenous fistula and three patients had a
synthetic arteriovenous graft
antiretroviral medications in this study, the natural his-
tory of viral suppression, and issues of follow-up and
noncompliance. Of note, the comparison of CD4 lympho-
cyte count and HIV RNA level at baseline and at the
time of data collection among patients alive at the time
of data collection may be affected by the exclusion of
patients who died during the course of the study. While
this introduces the possibility of informative censoring,Fig. 1. Dosing strategies. (A ) Frequency of dosing strategies for lami-
vudine. Dose for end-stage renal disease (ESRD) patient suggested at the exclusion of patients who died during the course of
50 mg initially, then 25 mg each thereafter. **Patient received 150 mg the study minimizes the effect of their preterminal statusthree times a week (following each dialysis treatment. (B ) Frequency
on the measurement of these parameters and reflects aof dosing strategies for zidovudine. Dose for ESRD suggested at 100 mg
every 6 to 8 hours. †Patient received 100 mg three times a week (follow- more stable antiretroviral regimen among those patients
ing each dialysis treatment). included. This and prior studies have not assessed the
barriers to prescription among HIV-infected patients re-
ceiving renal replacement therapy, which will be essen-
tial in understanding the efficacy of these agents overallnot. This is consistent with prior studies demonstrating
the efficacy of antiretroviral agents in immune reconsti- and among subgroups of eligible or compliant patients.
There were substantial variations in dosing regimenstution [12, 22] and prolonged survival [10, 12]. Interest-
ingly, HIV RNA levels fell only slightly between the time for antiretroviral medications among patients in this
study. The variation of dosing of protease inhibitors andpatients began dialysis and the period of data collection.
While this may be a function of limited power afforded nonnucleoside reverse transcriptase inhibitors may be
related in part to the variations required by the use ofby this sample, it may further be a reflection of the varia-
tion in dosing regimen seen among patients receiving concurrent medications (other antiretroviral, antimyco-
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bacterial, or antiepilieptic medications). For instance, data are unable to examine those factors that might result
in a survival bias, selecting patients with a decreasedlower doses of ritonavir (e.g., 100 to 200 mg/day) may
be used as a “booster” agent in conjunction with other mortality risk prior to or following the beginning of renal
replacement therapy. While this analysis has attemptedprotease inhibitors to permit their prescription at smaller
doses or decreased frequency. Among the nucleoside to minimize this bias through the inclusion of patients
based on initiation of dialysis following January 1, 1998,reverse transcriptase inhibitors, however, there was con-
siderable variation in the dosing of lamivudine and zido- the measurements of current clinical parameters such as
CD4 lymphocyte count and HIV RNA level were strati-vudine. The impact of this variation in dosing on out-
comes cannot be determined from these data but may fied on the basis of vital status to obviate the effect of
include the effects of both underdosing with decreased any preterminal events on the measures of these prevalent
therapeutic benefit and subadequate viral suppression characteristics among patients currently receiving dialysis.
in some cases and overdosing and the potential exposure
to increased toxicity related to the medications. As few
CONCLUSIONstudies adequately establish the pharmacokinetics and
This study describes the clinical and demographicsuggested dosing regimens for these agents among pa-
characteristics as well as the clinical practice patterns oftients with decreased renal function and patients receiv-
antiretroviral prescription among HIV-infected patientsing dialysis [23–28], this remains an area of essential
receiving renal replacement therapy in the post-HAARTresearch toward establishing the most efficacious treat-
era. Based on these data, additional questions in the carement regimens for HIV-infected patients on dialysis.
of the HIV-infected ESRD patient should be examined.While the use of antiretroviral medications may be
HIV-infected patients with renal disease who undergoimpacted by a number of factors such as potential to
renal biopsy have differences in the distribution of histo-adhere to therapy, patient interest in therapy, risk of
logic and clinical diagnoses as compared with patientstoxicity and drug interactions, current clinical practice
not undergoing biopsy. From a health service perspec-guidelines suggest that therapy be initiated among pa-
tive, this likely represents a substantial rate of misdiagno-tients who are either symptomatic with CD4 lymphocyte
sis. At the patient level, more aggressive diagnostic eval-counts 200 cells or asymptomatic patients with CD4
uation using renal biopsy may result in the ability tolymphocyte counts of200 cells [29]. This study demon-
provide directed treatment. The impact of this on out-strated that a significant proportion of patients with CD4
comes is not known. Further, the mechanism and impactcount 200 cells were not receiving therapy at the time
of the substantial rate of coinfection with hepatitis Cof data collection. As these data do not allow the exami-
nation of other more subjective factors that affect the suggests that this may become an important focus of
individualized decision to begin therapy, they suggest future research as outcomes for these patients improve.
that antiretroviral therapy may be underutilized among Finally, the wide variation in dosing of antiretroviral
patients who may receive the greatest benefit. medications suggests that there are subgroups of patients
This study demonstrated that a high proportion of who are not receiving the appropriate dose to maximally
HIV-infected patients receiving dialysis are coinfected suppress viral replication or minimize drug toxicity. As
with hepatitis C. While estimates vary, studies of preva- little information is available on the pharmacokinetics
lent dialysis patients estimate that between 8% and 36% of many of these medications and the number of HIV-
of patients in North America have a test positive for infected patients receiving renal replacement therapy
hepatitis C [30, 31]. Because of the cross-sectional design is expected to grow at an exponential rate (abstract;
of this study, it cannot be determined if these patients Schwartz EJ et al, J Am Soc Nephrol 11:165a, 2000),
were exposed to hepatitis C before or after beginning investigation of dosing and efficacy of these medications
renal replacement therapy. Because of the association in this population is essential. Based on the projected
between hepatitis C infection and intravenous drug use, growth of the population of HIV-infected patients with
it is likely that a number of patients were coinfected prior ESRD, this study provides epidemiologic and clinical
to the initiation of renal replacement therapy. Future information that describes the clinical needs of this popu-
research will be required to determine the effect of co- lation.
infection with HIV-1 and hepatitis C on the rate of pro-
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